Cosmos Health Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cosmos Health Inc. (NASDAQ: COSM) operates as a diversified, vertically integrated global pharmaceutical holding company that develops, manufactures, and distributes proprietary nutraceuticals, branded generics, over-the-counter medications, medical devices, cosmetics, food supplements, and healthcare products; its core brands include Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub, with additional offerings in vitamins, minerals, herbal extracts, and specialized root extracts produced under European Good Manufacturing Practices through subsidiary Cana Laboratories S.A. The company serves retail pharmacies, wholesale distributors, hospitals, and healthcare providers with a broad portfolio encompassing prescription drugs, OTC products, and nutraceuticals targeted at wellness, prevention, and therapeutic needs in areas such as obesity, diabetes, and cancer. Founded in 2009 and headquartered in Chicago, Illinois, Cosmos Health maintains operations across Europe, the UK, Asia, and North America, with key facilities in Thessaloniki and Athens, Greece, and Harlow, UK; it also provides healthcare distribution through EU and UK subsidiaries and has expanded into telehealth via its acquisition of ZipDoctor, Inc. in Texas, USA. In recent developments, Cosmos Health launched a long-term strategic partnership with Prime Ledger LLC on December 3, 2025, to manage its $300 million treasury facility, implement blockchain-based controls and reporting, and tokenize high-value intellectual property assets. The company commenced U.S. operations in September 2025 with its Sky Premium Life brand, leveraging local manufacturing to enter the $164 billion nutraceuticals market, while advancing R&D initiatives including AI-enhanced drug repurposing, nanotechnology for dietary supplements, and proprietary complex generics. CEO Greg Siokas increased his ownership by acquiring 301,101 shares in late 2025, signaling confidence amid record Q3 2025 results, and the firm diversified investments with Ethereum purchases totaling $2 million.
Company News
Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion
Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days
Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
Reviewing Cosmos Health (NASDAQ:COSM) & Community Health Systems (NYSE:CYH)
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
Cosmos Health: A Company Transformed — 2026 Year-to-Date
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term
Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels